Healthcare Professional Check

This website is intended for diabetes healthcare professionals. Click one of the options below to access the content.

You are here

Convenience, Compliance and Overcoming Clinical Inertia for Primary Care Physicians

for Primary Care Physicians

This course reviews the practical aspects of basal insulin–glucagon-like peptide-1 (GLP-1) receptor agonist combination therapy, and shows how fixed-dose combination therapies provide added convenience that may help overcome clinical inertia related to insulin therapy. Clinical data will be presented to demonstrate how the efficacy and safety of basal insulin–GLP-1 receptor agonist combination therapy surpasses that of the individual components. After completing the course, participants will be able to identify patients for whom treatment with basal insulin–GLP-1 receptor agonist combination therapy may be a viable option, and know how to best manage these patients.

Course contents

  • Webcast

    Clinical inertia

    • What is clinical inertia?
    • Reasons for not achieving targets: physician and patient barriers
    • Rationale for earlier insulin initiation
    • Methods for overcoming clinical inertia (illustrate this topic with a clinical case
  • Roundtable

    Matching insulin treatment to patient

    • Guideline recommendations on a patient-centred approach to disease management 
    • Understand the role of FPG, PPG, and body weight when choosing therapy 
    • Use of insulin with oral antidiabetes agents or GLP-1 RAs
    • Practical considerations when choosing the best treatment
    • The role of new insulin treatment combination
  • Hallway conversation

    Convenience of fixed-ratio basal insulin–GLP-1 RA combination therapies

    • Flexibility with regards to timing and dosing
    • Which patients may benefit most from this combination
    • Potential to improve adherence and overcome clinical inertia
  • Selected article

    Clinical inertia in intensifying therapy among people with type 2 diabetes treated with basal insulin

  • Selected article

    Role of incretin-based therapies and sodium-glucose co-transporter-2 inhibitors as adjuncts to insulin therapy in Type 2 diabetes, with special reference to IDegLira

  • Selected article

    Standards of Medical Care in Diabetes-2015 Abridged for Primary Care Providers

Courses are now online!

Register for the Insulin Educational program and start any available content whenever you want. You can sign up to the E-alert list to be notified when new courses or course modules are uploaded.

Search this site

Search form


Developed by Elsevier B.V., supported by an unrestricted educational grant from Novo Nordisk